BACKGROUND: Painful diabetic neuropathy is an important therapeutic challenge as the efficacy of analgesic drugs in this setting is still unsatisfactory. Monotherapy with available treatments is often not sufficient and a combination of drugs is necessary. Trazodone (TRZ) is a compound with a multi-modal mechanism of action, being a serotonin-2 antagonist/reuptake inhibitor developed and approved for the treatment of depression in several countries. Previous clinical trials suggest a possible beneficial effect of low doses of trazodone for the treatment of patients affected by painful diabetic neuropathy. OBJECTIVE: This phase II study was designed to collect data on the efficacy and safety of low doses of TRZ combined with gabapentin after 8 weeks of treatment in patients affected by painful diabetic neuropathy. METHODS: This was a randomized, double-blind, placebo-controlled, multi-center, international, prospective study. Male and female diabetic patients aged 18-75 years and affected by painful diabetic neuropathy were eligible for enrollment. Subjects were randomized (1:1:1 ratio) to TRZ30 (10 mg three times daily for 8 weeks) or TRZ60 (20 mg three times daily for 8 weeks) or placebo. Gabapentin as background therapy was administered in open-label conditions to all patients. The primary endpoint was the change from baseline of the Brief Pain Inventory Short Form item 5 to week 8. Secondary endpoints included the other Brief Pain Inventory Short Form items, and the assessment of anxiety, sleep, quality of life, patient's improvement, and safety. RESULTS: One hundred and forty-one patients were included in the intention-to-treat population: 43 allocated to the TRZ30 group, 50 to the TRZ60 group, and 48 to the placebo group. After 8 weeks, the mean changes of Brief Pain Inventory Short Form item 5 from baseline were - 3.1, - 2.6, and - 2.5 in the TRZ30, TRZ60, and placebo groups, respectively. No statistically significant differences between groups were seen. Nevertheless, a better trend was observed for TRZ30 vs placebo (95% confidence interval - 1.30, 0.15; p = 0.1179), on top of the background effect of gabapentin administered to all study groups. 62.8% of patients achieved a ≥ 50% reduction in the TRZ30 group, 54% in the TRZ60 group, and 45.8% in the placebo group. At the same time, a statistically significant improvement was observed in Brief Pain Inventory Short Form item 6 for TRZ30 vs placebo (95% confidence interval - 1.54, - 0.07; p = 0.0314). No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders. CONCLUSIONS: All treatment groups showed a clinically meaningful pain improvement; nevertheless, patients in the TRZ30 treatment group reported better efficacy outcomes. This finding suggests that low doses of TRZ could be useful for treating painful diabetic neuropathy, and support further adequately powered confirmatory trials investigating the efficacy of TRZ. CLINICAL TRIAL REGISTRATION: NCT03202979, date of registration: 29/06/2017.

Angelini Pharma S p A Viale Amelia 70 Rome Italy

Department of Human Neuroscience Sapienza University of Rome Rome Italy

Neurological Unit Regional Hospital Pardubice Pardubice Czech Republic

NZOZ Neuromed M i M Nastaj Sp P Lublin Poland

Silmedic Sp z o o Katowice Poland

Zobrazit více v PubMed

Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015;6(3):432–444. doi: 10.4239/wjd.v6.i3.432. PubMed DOI PMC

Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tolle T, Bouhassira D, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The ‘COMBO-DN Study’: a multinational, randomized, double-blind, parallel group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. doi: 10.1016/j.pain.2013.05.043. PubMed DOI

Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354. doi: 10.1097/00002508-200211000-00002. PubMed DOI

Blesneac I, Themistocleous AC, Fratter C, Conrad LJ, Ramirez JD, Cox JJ, et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 2018;159(3):469–480. doi: 10.1097/j.pain.0000000000001116. PubMed DOI PMC

Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag. 2005;30:374–385. doi: 10.1016/j.jpainsymman.2005.04.009. PubMed DOI

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl. 1):8–14. doi: 10.1002/dmrr.2239. PubMed DOI

Centre for Clinical Practice at NICE (UK). Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. National Institute for Health and Care Excellence (UK). Clinical Guidelines 173, November 2013, last updated July 2019. PubMed

Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, On Behalf of the Toronto Expert Panel on Diabetic Neuropathy et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–638. doi: 10.1002/dmrr.1225. PubMed DOI

Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl.):S3–S14. doi: 10.4065/mcp.2009.0649. PubMed DOI PMC

Sawnyok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001;26:21–29. PubMed PMC

Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin–norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7(4):331–336. doi: 10.2174/157015909790031201. PubMed DOI PMC

Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–1049. doi: 10.1007/s40263-012-0010-5. PubMed DOI PMC

Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536–546. doi: 10.1017/S1092852900024020. PubMed DOI

Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305–1322. PubMed

Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanism of action. J Clin Psychiatry. 1998;59(Suppl. 4):5–14. PubMed

Stahl SM. Essential psychopharmacology of depression and bipolar disorder. 2. New York: Cambridge University Press; 2000.

Aira Z, Buesa I, Gallego M, García del Caño G, Mendiable N, Mingo J, et al. Time-dependent cross talk between spinal serotonin 5-HT2A receptor and mGluR1 subserves spinal hyperexcitability and neuropathic pain after nerve injury. J Neurosci. 2012;32(39):13568–13581. doi: 10.1523/JNEUROSCI.1364-12.2012. PubMed DOI PMC

Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, et al. Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology. 2012;62(7):2184–2191. doi: 10.1016/j.neuropharm.2012.01.010. PubMed DOI

Olivero G, Grilli M, Vergassola M, Bonfiglio T, Padolecchia C, Garrone B, et al. 5-HT2A-mGlu2/3 receptor complex in rat spinal cord glutamatergic nerve endings: a 5-HT2A to mGlu2/3 signalling to amplify presynaptic mechanism of auto-control of glutamate exocytosis. Neuropharmacology. 2018;133:429–439. doi: 10.1016/j.neuropharm.2018.02.030. PubMed DOI

Khurana RC. Treatment of painful diabetic neuropathy with trazodone. JAMA. 1983;250(11):1392. doi: 10.1001/jama.1983.03340110016015. PubMed DOI

Wilson RC. The use of low dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. 1999;89(9):468–471. doi: 10.7547/87507315-89-9-468. PubMed DOI

Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23:129–138. PubMed

Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manag. 2005;29(4):401–410. doi: 10.1016/j.jpainsymman.2004.06.018. PubMed DOI

Finnerup NB, Haroutounian S, Baron R, Dworkin RH, Gilron I, Haanpaa M, et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain. 2018;159(11):2339–2346. doi: 10.1097/j.pain.0000000000001340. PubMed DOI PMC

Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast. 2017;2017:9724371. PubMed PMC

Ferini-Strambi L. Neuropathic Pain and Sleep: A Review. Pain Ther. 2017;6(Suppl 1):19–23. PubMed PMC

Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707–17. PubMed

Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–288. doi: 10.1159/000447034. PubMed DOI

Karki BR, Prasai P, Ruhela A, Sedhai YR. Trazodone Overdose-Induced Prinzmetal's Angina Pectoris. Proc (Bayl Univ Med Cent) 2019;33(1):75–76. PubMed PMC

Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016;13(2):161–168. doi: 10.1177/1740774515602688. PubMed DOI PMC

Efficacy and Safety of Trazodone and Gabapentin Fixed-Dose Combination in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose-Finding Study

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03202979